Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947347568> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2947347568 abstract "e15663 Background: For over ten years the most stimulating results in systemic therapy for advanced HCC derived from the use of sorafenib (S). But in the last two years several drugs, in particular other multikinase inhibitors like lenvatinib (L), regorafenib (R), cabozantinib (C), proved to be effective both as an alternative or a sequential therapy to sorafenib. In this widened and rapidly increased scenario, without any head-to-head trial, clinicians struggle to define the best drug and the best treatment sequence. Aim of the first part of this project is to evaluate the activity of different treatment sequences in HCC cell lines to pave the way to a future clinical trial investigating their efficacy. Methods: Compounds of S, R, L and C were dissolved in DMSO and aliquoted. HepG2 cell line, obtained from ECACC (Salisbury, UK), was seeded at the density of 3 x 104 cells/ml. After 24 h of incubation, compounds or vehicle (DMSO) were added. Treatments were performed in single administration and six replicates were carried out for each dose. At 48h post-treatment, cells were fixed and stained with acid solution. The absorbance was measured at 520 nm using an ELISA reader (BioTek Instruments, USA). The assay was also performed with the sequences of: S-R, S-C, L-R, L-C (first line treatments for 48h followed by the second compound for 48h). Higher doses than the minimum inhibiting one were tested. Results: S showed superior activity than L as first line compound. In the sequence assay S-C and S-R seems to have the best results in terms of cell viability. After L the best compound appears to be R. See table. Conclusions: Our results showed relevant variations in cell viability with different drug sequences. Already planned analyses in the RISE-HEP project in vivo and in humans are mandatory to confirm which sequence would have the highest efficacy.[Table: see text]" @default.
- W2947347568 created "2019-06-07" @default.
- W2947347568 creator A5006012062 @default.
- W2947347568 creator A5007630725 @default.
- W2947347568 creator A5007635105 @default.
- W2947347568 creator A5021213021 @default.
- W2947347568 creator A5021477463 @default.
- W2947347568 creator A5034035272 @default.
- W2947347568 creator A5035812888 @default.
- W2947347568 creator A5040616139 @default.
- W2947347568 creator A5048029557 @default.
- W2947347568 creator A5051507235 @default.
- W2947347568 creator A5066886113 @default.
- W2947347568 creator A5079690240 @default.
- W2947347568 date "2019-05-20" @default.
- W2947347568 modified "2023-10-02" @default.
- W2947347568 title "RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines." @default.
- W2947347568 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15663" @default.
- W2947347568 hasPublicationYear "2019" @default.
- W2947347568 type Work @default.
- W2947347568 sameAs 2947347568 @default.
- W2947347568 citedByCount "0" @default.
- W2947347568 crossrefType "journal-article" @default.
- W2947347568 hasAuthorship W2947347568A5006012062 @default.
- W2947347568 hasAuthorship W2947347568A5007630725 @default.
- W2947347568 hasAuthorship W2947347568A5007635105 @default.
- W2947347568 hasAuthorship W2947347568A5021213021 @default.
- W2947347568 hasAuthorship W2947347568A5021477463 @default.
- W2947347568 hasAuthorship W2947347568A5034035272 @default.
- W2947347568 hasAuthorship W2947347568A5035812888 @default.
- W2947347568 hasAuthorship W2947347568A5040616139 @default.
- W2947347568 hasAuthorship W2947347568A5048029557 @default.
- W2947347568 hasAuthorship W2947347568A5051507235 @default.
- W2947347568 hasAuthorship W2947347568A5066886113 @default.
- W2947347568 hasAuthorship W2947347568A5079690240 @default.
- W2947347568 hasConcept C121608353 @default.
- W2947347568 hasConcept C126322002 @default.
- W2947347568 hasConcept C143998085 @default.
- W2947347568 hasConcept C185926286 @default.
- W2947347568 hasConcept C2778019345 @default.
- W2947347568 hasConcept C2778695046 @default.
- W2947347568 hasConcept C502942594 @default.
- W2947347568 hasConcept C530470458 @default.
- W2947347568 hasConcept C71924100 @default.
- W2947347568 hasConceptScore W2947347568C121608353 @default.
- W2947347568 hasConceptScore W2947347568C126322002 @default.
- W2947347568 hasConceptScore W2947347568C143998085 @default.
- W2947347568 hasConceptScore W2947347568C185926286 @default.
- W2947347568 hasConceptScore W2947347568C2778019345 @default.
- W2947347568 hasConceptScore W2947347568C2778695046 @default.
- W2947347568 hasConceptScore W2947347568C502942594 @default.
- W2947347568 hasConceptScore W2947347568C530470458 @default.
- W2947347568 hasConceptScore W2947347568C71924100 @default.
- W2947347568 hasLocation W29473475681 @default.
- W2947347568 hasOpenAccess W2947347568 @default.
- W2947347568 hasPrimaryLocation W29473475681 @default.
- W2947347568 isParatext "false" @default.
- W2947347568 isRetracted "false" @default.
- W2947347568 magId "2947347568" @default.
- W2947347568 workType "article" @default.